Rocket Pharmaceuticals (RCKT) Presents At 41st Annual Healthcare Conference - Slideshow

Months post gene therapy 23 For 5 patients, increased BM CFC MMC resistance ranging from 51% to 94% was observed at 18 to 24 months post– RP-L102 administration 25 Disease etiology 26 24 Months post gene therapy RP-L201: LAD-I INVESTOR DECK INVESTOR DECK INVESTOR DECK 41st Annual J.P. Morgan Healthcare Conference Company Presentation Gaurav Shah, MD Chief Executive Officer January 9, 2023 DISCLAIMER Various statements in this presentation concerning Rocket's future expectations, plans and prospects, includi ...